Mumbai, Maharashtra, India
Inogent Laboratories (Inogent Labs), a Hyderabad-based custom synthesis and API manufacturing company, today announced the appointment of Rajiv Varma as the new President of the company.
Rajiv Varma has more than 32 years of experience in the pharmaceutical industry and has worked with the leading pharmaceutical companies before joining Inogent Labs. Starting his career with ICI India Ltd in 1975 as a management trainee he went on to become the Senior Vice-President of the company in 2002. He then moved to Nicholas Piramal India Ltd as Senior Vice President in 2004 and Cadila pharmaceutical Ltd. as President of API Business in 2005 before moving to Inogent Labs.
D.S. Brar, Chairman, GVK Biosciences said,"We welcome Rajiv Varma as President of Inogent Labs. His varied experience will bring immense value to the organization and help Inogent achieve leadership status in its business segment".
In his new role as President, Varma will be responsible for Inogent operations and help the company grow as a leading contract research and custom manufacturing services provider.
About Inogent Laboratories:
Inogent is a fast growing Custom Chemical Synthesis and API Manufacturing Company located at Hyderabad, India. It is an ISO (9001-2000) certified company accredited by WHO - GMP. The Company has state-of-the-art process and analytical R&D laboratories, pilot plant, kilo lab and two production blocks and works with both large and mid-size Pharma companies who have audited and approved its manufacturing and scale up facilities. The Company has more than 225 employees working in R&D, Manufacturing and Support functions. Inogent is a GVK BIO associate company.
To view the photograph, please click on the link given below:
Rajiv Varma
Source: Inogent Laboratories (Business Wire India)
Press release presented here is sourced from the Source mentioned above and is provided on as-is basis. Please contact the Company / Source directly for any further information in regard to this release. This website will be unable to assist you in regard to the accuracy or correctness of information in this release.